Search Results - "Van Tine, Brian Andrew"

Synovial Sarcoma: Current Concepts and Future Perspectives by Stacchiotti, Silvia, Van Tine, Brian Andrew

“…Synovial sarcoma (SS) is a rare sarcoma driven by a translocation between SS18 and SSX 1, 2, or 4. With approximately 800 to 1,000 cases a year in the United…”
Get full text

Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers by Kremer, Jeff Charles, Prudner, Bethany Cheree, Lange, Sara Elaine Stubbs, Bean, Gregory Richard, Schultze, Matthew Bailey, Brashears, Caitlyn Brook, Radyk, Megan DeAnna, Redlich, Nathan, Tzeng, Shin-Cheng, Kami, Kenjiro, Shelton, Laura, Li, Aixiao, Morgan, Zack, Bomalaski, John Stephen, Tsukamoto, Takashi, McConathy, Jon, Michel, Loren Scott, Held, Jason Matthew, Van Tine, Brian Andrew

“…Targeting defects in metabolism is an underutilized strategy for the treatment of cancer. Arginine auxotrophy resulting from the silencing of argininosuccinate…”
Get full text

Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts by Burgess, Melissa Amber, Bolejack, Vanessa, Schuetze, Scott, Van Tine, Brian Andrew, Attia, Steven, Riedel, Richard F., Hu, James S, Davis, Lara Emily, Okuno, Scott H., Priebat, Dennis A., Movva, Sujana, Reed, Damon R., D'Angelo, Sandra P., Lazar, Alexander J., Keung, Emily Zhi-Yun, Reinke, Denise K., Baker, Laurence H., Maki, Robert G., Patel, Shreyaskumar, Tawbi, Hussein Abdul-Hassan

“…Abstract only 11015 Background: Immune checkpoint inhibitors have demonstrated activity in multiple tumor types but their activity in soft tissue sarcomas…”
Get full text

Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105) by Gounder, Mrinal M., Mahoney, Michelle R., Van Tine, Brian Andrew, Ravi, Vinod, Attia, Steven, Deshpande, Hari Anant, Gupta, Abha A., Milhem, Mohammed M., Conry, Robert Martin, Movva, Sujana, Pishvaian, Michael J., Crawford, Jeffrey, Sabagh, Tarek, Maki, Robert G., Tap, William D., Lefkowitz, Robert A, Agaram, Narasimhan P, Wright, John Joseph, Dueck, Amylou C., Schwartz, Gary K.

“…Abstract only…”
Get full text

Effect of combined treatment with sipuleucel-T and IL-15 on tumor control, tumor-infiltrating immune effectors, and key mediators of immunoresistance in a preclinical prostate cancer model by Pachynski, Russell Kent, Saeed, Muhammad Azeem, Peng, Bo, Van Tine, Brian Andrew, Sheikh, Nadeem Anwar, Fehniger, Todd A.

“…177 Background: Sipuleucel-T (sip-T) is an autologous therapeutic vaccine produced using a tumor antigen-cytokine fusion protein, and the only FDA approved…”
Get full text

Management of localized extremity and retroperitoneal soft tissue sarcoma by Abaricia, Sarah, Van Tine, Brian Andrew

“…The optimal management of localized soft tissue sarcomas of the extremities and retroperitoneum involves a high volume multidisciplinary team with expertise in…”
Get full text

Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator’s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy by Lacuna, Kristine Peregrino, Mandrekar, Sumithra J., Allred, Jacob B., Berg, Stephanie A., Hensley, Martee Leigh, Van Tine, Brian Andrew, George, Suzanne, Schwartz, Gary K., Ingham, Matthew

“…TPS11584 Background: Uterine leiomyosarcoma (uLMS) is an aggressive sarcoma subtype with frequent metastatic relapse. Advanced uLMS is treated with…”
Get full text

Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas by Martín-Broto, Javier, Moura, David S, Van Tine, Brian A

“…Sarcomas are mesenchymal tumors, encompassing more than 175 subtypes, each one with their own genetic complexities. As a result, immunotherapy approaches have…”
Get full text

A phase 1b study of unesbulin (PTC596) plus dacarbazine for the treatment of patients with locally recurrent, unresectable, or metastatic relapsed/refractory leiomyosarcoma by Van Tine, Brian Andrew, Ingham, Matthew, Attia, Steven, Meyer, Christian Frederick, Baird, John, D'Silva, Dhiren, O'Keefe, Kylie, Maliakal, Pius, Wahba, Mona M., Weetall, Marla, Schwartz, Gary K.

“…11507 Background: Leiomyosarcoma (LMS) is one of the most common subtypes of soft tissue sarcoma and is associated with high risk of relapse and a poor…”
Get full text

Primary efficacy and safety of letetresgene autoleucel (lete-cel; GSK3377794) pilot study in patients with advanced and metastatic myxoid/round cell liposarcoma (MRCLS) by D'Angelo, Sandra P., Druta, Mihaela, Van Tine, Brian Andrew, Liebner, David A., Schuetze, Scott, Nathenson, Michael, Holmes, Andrew P., D'Souza, Jimson, Kapoor, Gurpreet Singh, Zajic, Stefan, Somaiah, Neeta

“…11500 Background: Lete-cel is an autologous T-cell therapy targeting NY-ESO-1 tumors using a genetically modified, high-affinity T-cell receptor. MRCLS is a…”
Get full text

RINGSIDE phase 2/3 trial of AL102 for treatment of desmoid tumors (DT): Phase 2 results by Gounder, Mrinal M., Jones, Robin Lewis, Chugh, Rashmi, Agulnik, Mark, Singh, Arun S., Van Tine, Brian Andrew, Andelkovic, Vladimir, Choy, Edwin, Lewin, Jeremy Howard, Ratan, Ravin, Gordon, Gary B., Yovell, Jonathan, Gutierrez, Andres A., Kasper, Bernd

“…11515 Background: For patients with desmoid tumors (DT, aggressive fibromatosis), systemic therapy that results in tumor regression, symptom improvement and…”
Get full text

A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma by Bose, Sminu (Sam), Ge, Liner, Lee, Shing M, Van Tine, Brian Andrew, Agulnik, Mark, Weiss, Mia C., Lacuna, Kristine Peregrino, Sender, Naomi, Sta Ana, Sarah, Hsu, Frank J., Schwartz, Gary K., Ingham, Matthew

“…11565 Background: Immune checkpoint inhibitors have limited efficacy in soft tissue sarcoma (STS) due to insufficient T-cell activation and infiltration by…”
Get full text

STK11 alterations as predictive biomarkers of resistance to immune checkpoint inhibitors in multiple cancers with mismatch repair gene alterations by Iglesia, Michael, Khushman, Moh'd M., Lim, Kian-Huat, Van Tine, Brian Andrew, Liu, Jingxia, Pedersen, Katrina Sophia, Liu, Xiuli, Trikalinos, Nikolaos, Suresh, Rama, Aranha, Olivia, Grierson, Patrick, Tan, Benjamin R., Govindan, Ramaswamy

“…2619 Background: STK11 is an important tumor suppressor gene that encodes for a serine-threonine kinase involved in a variety of metabolic functions. STK11…”
Get full text

Phase (Ph) 1b/2 evaluation of olaratumab in combination with gemcitabine and docetaxel in advanced soft tissue sarcoma (STS) by Attia, Steven, Villalobos, Victor Manuel, Hindi, Nadia, Van Tine, Brian Andrew, Wagner, Andrew J., Chmielowski, Bartosz, Levy, Donna Elise, Ceccarelli, Matteo, Jones, Robin Lewis, Dickson, Mark Andrew

“…Abstract only 11517 Background: Doxorubicin (doxo) remains standard first-line therapy for advanced STS. Doxo in combination with olaratumab (O) demonstrated…”
Get full text

A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST) by George, Suzanne, Heinrich, Michael C., Somaiah, Neeta, Van Tine, Brian Andrew, McLeod, Robert, Laadem, Abderrahmane, Cheng, Ben, Nishioka, Satoshi, Kundu, Madan Gopal, Qian, Xiaozhong, Lau, Yvonne Y., Tran, Brittany, Kumar, Prasanna, Dosunmu, Ololade, Shi, Julia, Naito, Yoichi

“…11512 Background: GPR20 is selectively and abundantly expressed in GISTs, the most common sarcoma of digestive tract. DS-6157a is an anti-GPR20 antibody-drug…”
Get full text

Identification of response stratification factors from pooled efficacy analyses of afamitresgene autoleucel (“Afami-cel” [Formerly ADP-A2M4]) in metastatic synovial sarcoma and myxoid/round cell liposarcoma phase 1 and phase 2 trials by D'Angelo, Sandra P., Attia, Steven, Blay, Jean-Yves, Strauss, Sandra J., Valverde Morales, Claudia Maria, Abdul Razak, Albiruni Ryan, Van Winkle, Erin, Annareddy, Thejo, Sattigari, Chandra, Diamantopoulos, Evangelo, Williams, Dennis, Norry, Elliot, Biswas, Swethajit, Araujo, Dejka M., Van Tine, Brian Andrew

“…11562 Background: Afami-cel is an autologous, HLA-A*02-restricted, specific peptide enhanced affinity receptor, T-cell therapy engineered to target MAGE-A4+…”
Get full text

Multi-institutional analysis of outcomes in patients with dedifferentiated chondrosarcoma (DDCS) by Bui, Nam, Dietz, Hilary, Hirbe, Angela C., Ganjoo, Kristen N., Van Tine, Brian Andrew, Keedy, Vicki Leigh, Davis, Elizabeth J.

“…Abstract only 11028 Background: DDCS is a rare bone tumor with a poor prognosis. While no standard therapy exists, NCCN guidelines recommend osteosarcoma…”
Get full text

Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma by Van Tine, Brian Andrew, Eulo, Vanessa, Toeniskoetter, Jacqui, Ruff, Tyler, Luo, Jingqin, Kemp, Lindsey, Moreno Tellez, Cristiam, Weiss, Mia C., Hirbe, Angela C., Meyer, Christian Frederick, Elias, Anthony D., Diamond, Mark, Hartner, Lee P., Bui, Nam, Ganjoo, Kristen N., Maki, Robert G., Wilky, Breelyn A.

“…LBA11504 Background: Cabozantinib (C) has been combined successfully with either PD-1 or CTLA-4 inhibition in cancer clinical trials. The combination of…”
Get full text

MT-6402, an engineered toxin body (ETB) targeting PD-L1: Interim efficacy and safety data by Barve, Minal A., Van Tine, Brian Andrew, Redman, Rebecca A., Powell, Steven Francis, Edenfield, William Jeffery, Peguero, Julio Antonio, Villaflor, Victoria Meucci, Stein, Karen, Moore, Chris, Orlandella, Rachael, Khanna, Swati, Dekker, Joseph, Ferrati, Silvia, Charoenthongtrakul, Soratree, Liu, Yanning, Dabovic, Kristina, Spigel, David R.

“…2552 Background: MT-6402, an engineered toxin body (ETB) , has been designed to be effective in patients (pts) previously treated with checkpoint inhibitors…”
Get full text

The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma by Van Tine, Brian Andrew, Ganjoo, Kristen N., Blay, Jean-Yves, Valverde, Claudia, Araujo, Dejka M., Abdul Razak, Albiruni Ryan, Le Cesne, Axel, Schuetze, Scott, Wagner, Michael J, Attia, Steven, Forcade, Edouard, Druta, Mihaela, Pollack, Seth, Bai, Jane, Bayer, Paige, Van Winkle, Erin, Norry, Elliot, McAlpine, Cheryl, Williams, Dennis, D'Angelo, Sandra P.

“…11563 Background: Afami-cel is an autologous, T-cell receptor (TCR) T-cell therapy to treat human leukocyte antigen (HLA) A*02–eligible patients (pts) with…”
Get full text